Follicular lymphoma - treatment and prognostic factors

Follicular lymphoma is the second most frequent non-Hodgkin lymphoma accounting for about 10-20% of all lymphomas in western countries. The median age at diagnosis is 60 years old. The clinical presentation is usually characterized by asymptomatic peripheral adenopathy in cervical, axillary, inguinal and femoral regions. Treatment options for patients with naïve or recurrent follicular lymphoma are still controversial, ranging from a "watch and wait" policy to hematopoietic stem cell transplantation. More recently, the availability of rituximab has substantially changed follicular lymphoma therapeutic approaches to such an extent that R-Chemo is now the standard induction first-line treatment. This review provides a general overview of the state of the art in the management of follicular lymphoma and also, a brief description regarding the current prognostic tools available for treatment decisions.

• Publication year

  2012

• Venue

  Revista Brasileira de Hematologia e Hemoterapia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5581/1516-8484.20120015PMID 23049385PMCID 3459616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

  2011cited by this paper
• Follicular lymphoma: 2011 update on diagnosis and management

  2011cited by this paper
• Treatment strategies in advanced stage follicular lymphoma.

  2011cited by this paper
• Improved survival in patients with early stage low‐grade follicular lymphoma treated with radiation

  2010cited by this paper
• Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.

  2009cited by this paper
• Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.

  2009cited by this paper
• Prognostic tools in follicular lymphomas

  2009cited by this paper
• Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

  2008cited by this paper
• Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.

  2008cited by this paper
• Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

  2008cited by this paper
• Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

  2008cited by this paper
• Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma

  2007cited by this paper
• Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

  2007cited by this paper
• Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.

  2007cited by this paper
• Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.

  2007cited by this paper
• Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

  2006cited by this paper
• Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.

  2006cited by this paper
• Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

  2006cited by this paper
• Meta-analysis to evaluate the role of interferon in follicular lymphoma.

  2005cited by this paper
• New treatment options have changed the survival of patients with follicular lymphoma.

  2005cited by this paper
• Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t

  2005cited by this paper
• Follicular lymphoma international prognostic index.

  2004cited by this paper
• Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

  2004cited by this paper
• Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy.

  2004cited by this paper
• Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

  2003cited by this paper
• Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.

  2003cited by this paper
• Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

  2002cited by this paper
• Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

  2002cited by this paper
• Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.

  2000cited by this paper
• New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

  1998cited by this paper
• Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

  1997cited by this paper
• The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.

  1988cited by this paper

• Risk of Type II Diabetes Mellitus Among B‐Cell Non‐Hodgkin's Lymphoma Survivors

  2026cites this paper
• Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy

  2025cites this paper
• Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches

  2024cites this paper
• Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review

  2024cites this paper
• ORAL LYMPHOMA: A REPORT OF TWO CONTRASTING CASES

  2023cites this paper
• Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis

  2022cites this paper
• Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis

  2021cites this paper
• Spinal anesthesia in a patient on monoclonal antibody treatment: a poisoned chalice? A case report

  2021cites this paper
• Case Report: Spontaneous Remission of an Infraorbital Follicular B-Cell Lymphoma: Case Report and Review of the Literature

  2021cites this paper
• Function of Deptor and its roles in hematological malignancies

  2021cites this paper
• Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy

  2021cites this paper
• Copanlisib for the treatment of adults with relapsed follicular lymphoma

  2020cites this paper
• Fludarabina en el tratamiento del linfoma no Hodgkin folicular

  2020cites this paper
• MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers

  2020cites this paper
• CAR-T cell Therapy in B-cell Lymphoma

  2019cites this paper
• Thoracoscopic Diagnosis of Follicular Lymphoma Relapsing after 13 Years

  2019cites this paper
• Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada.

  2019cites this paper
• Current targeted therapies in lymphomas.

  2019cites this paper
• Follicular Lymphoma — Diagnosis and Survival Rate

  2019cites this paper
• The study of oncolytic viruses reproduction in organ cultures of human lymphoid tumors

  2019cites this paper
• Cancer Immunotherapy and the Immune Response in Follicular Lymphoma

  2018cites this paper
• Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals

  2018cites this paper
• Nanomedicines for the treatment of hematological malignancies

  2018cites this paper
• Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date

  2018cites this paper
• Diagnosis and treatment of follicular lymphoma: an update.

  2018cites this paper
• Gastric follicular lymphoma: A report of 3 cases and a review of the literature

  2018cites this paper
• Using Murine Models to Understand Tumor-Lymphoid Interactions: Spotlight on CLL and AITL

  2017cites this paper
• Using Murine Models to Investigate Tumor–Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma

  2017cites this paper
• Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies

  2017cites this paper
• Differential Expression of Bcl-2 Family Proteins Determines the Sensitivity of Human Follicular Lymphoma Cells to Dexamethasone-mediated and Anti-BCR-mediated Apoptosis

  2016cites this paper
• A Case of Chyloperitoneum Secondary to Follicular Lymphoma and a Review of Prognostic Implications

  2016cites this paper
• Lymphadenopathy: Differentiation between Tuberculosis and Other Non-Tuberculosis Causes like Follicular Lymphoma

  2016cites this paper
• Follicular Lymphoma Diagnosed With Medical Thoracoscopy.

  2016cites this paper
• Management of Hematologic Malignancies: Special Considerations in Pregnant Women

  2015cites this paper
• Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma

  2015cites this paper
• Lymphomes folliculaires

  2014cites this paper